Technical Analysis for HIK - Hikma Pharmaceuticals Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | -0.33% | |
| Spinning Top | Other | -0.33% | |
| Narrow Range Bar | Range Contraction | -0.33% | |
| Outside Day | Range Expansion | -0.33% | |
| Up 3 Days in a Row | Strength | -0.33% | |
| Up 4 Days in a Row | Strength | -0.33% | |
| NR7 | Range Contraction | -0.28% | |
| Narrow Range Bar | Range Contraction | -0.28% |
| Alert | Time |
|---|---|
| 20 DMA Resistance | about 20 hours ago |
| Rose Above Previous Day's High | about 20 hours ago |
| Rose Above 20 DMA | about 20 hours ago |
| Up 1% | about 20 hours ago |
| Rose Above Previous Day's High | 1 day ago |
Free Daily (Stock) Chart Reading
Hikma Pharmaceuticals Plc Description
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company's segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1,120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business' products include Argatroban, Fentanyl, Glycopyrrolate, Nicardipine and Phenylephrine.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pharmaceuticals Strength Pharmaceutical Products Supra Pharmaceutical Companies Dosage Forms North Africa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2221.4639 |
| 52 Week Low | 1710.5872 |
| Average Volume | 402,754 |
| 200-Day Moving Average | 1935.72 |
| 50-Day Moving Average | 1893.70 |
| 20-Day Moving Average | 1830.78 |
| 10-Day Moving Average | 1802.50 |
| Average True Range | 38.11 |
| RSI (14) | 44.44 |
| ADX | 22.89 |
| +DI | 16.91 |
| -DI | 26.79 |
| Chandelier Exit (Long, 3 ATRs) | 1823.18 |
| Chandelier Exit (Short, 3 ATRs) | 1874.32 |
| Upper Bollinger Bands | 1908.31 |
| Lower Bollinger Band | 1753.24 |
| Percent B (%b) | 0.39 |
| BandWidth | 8.47 |
| MACD Line | -24.32 |
| MACD Signal Line | -26.89 |
| MACD Histogram | 2.5621 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1864.00 | ||||
| Resistance 3 (R3) | 1866.67 | 1852.33 | 1855.50 | ||
| Resistance 2 (R2) | 1852.33 | 1839.35 | 1851.00 | 1852.66 | |
| Resistance 1 (R1) | 1832.67 | 1831.32 | 1825.50 | 1830.00 | 1849.83 |
| Pivot Point | 1818.33 | 1818.33 | 1814.75 | 1817.00 | 1818.33 |
| Support 1 (S1) | 1798.67 | 1805.35 | 1791.50 | 1796.00 | 1776.17 |
| Support 2 (S2) | 1784.33 | 1797.32 | 1783.00 | 1773.34 | |
| Support 3 (S3) | 1764.67 | 1784.33 | 1770.50 | ||
| Support 4 (S4) | 1762.00 |
